KPR Mill update

Reasons for buying:

Market Cap: ₹18,405 Cr (Bluechip stock)

Debt to Equity: 0.2

Return on Equity 5Y Avg: 23.14%

EPS - 5Y Growth: 26.92%

Price-earnings to growth (5Y): 0.83

5Y RoE Consistency - Sustained without losing 20% in any year

Buy date: 1-Aug-2022

Qty: 16 Price: ₹588.35 Buy EPS: 26.21

Buy date: 28-Oct-2022

Qty: 18 Price: ₹529 Buy EPS: 26.21

Will continue to add when a stock falls 10% as long as the ratios remain the same. The stock would take a long time to pay, it lost 10% since I bought it in August.

KPR Mill is an apparel manufacturer, securing revenues predominantly from India. It is mainly engaged in the business of manufacturing textiles consisting of yarn, fabrics, readymade garments, and wind power. Its core products are readymade knitted apparel, fabrics, melange, carded, and combed yarn. Its secondary segment includes sugar and others. The company has its production facilities in the state of Tamil Nadu in India.

Muthoot Finance Options update

Date: 30-09-2022

Sold MUTHOOTFIN OCT 800 PE lot 375 at ₹5 for a premium of ₹1875.

The margin required ₹51792.88 it will be a cash-secured put.

Reasons for selling:

The previous close was ₹1033

The strike price is 105 which is 23% lower and there are 27 days for expiry. Sold because the strike price is 23% below market price and even if it gets allocated I will try to do a wheel strategy.

Max loss is ₹3,00,000 if the company goes bankrupt.

Date: 27-10-2022

The option expired worthless, the price closed at ₹1041 and went as low as ₹1007.45 in between and made ₹1875. Was looking for a similar deal this month but could find any have to check the options chart.

Tech Mahindra Options update

Date: 30-09-2022

Sold TECHM OCT 800 PE at ₹2.35 for a premium of ₹1410.

Margin required ₹57,770.39.

Reasons for selling:

The previous close was ₹1,007

The strike price is ₹800 which is 20% lower and there are 27 days for expiry. Last time I made a profit of 100% in this stock, and even if it gets allocated I will try to do a wheel strategy.

Max loss is ₹4,80,000 if the company goes bankrupt.

Date: 27-10-2022

The option expired worthless, the price closed at ₹1075 and went as low as ₹984 in between and made ₹1410. Was looking for a similar deal this month but could find any have to check the options chart.

Jubilant Pharmova update

Reasons for buying:

Buy PE was reasonable at 10.64 and below 10 years PE median of 14.83.

Earnings have increased 6 times since 2013.

Return on equity is ok at 16.16%.

The market cap of the company is ₹10,006.84cr.

The debt of the company is ₹2,583.97cr with ₹671.32cr in cash. The debt is higher than my other investments but I think it's cheap, have to wait and see if I can make money on it.

Buy date: 28-Sep-2021

Qty: 16 Buy Price: ₹607 Buy EPS: ₹57.03 Buy PE: 10.64

Sell date: 27-Oct-2022

Qty:16 Price: ₹349.65 EPS: ₹10.24 PE: 34.14

The price of the stock is up about 3.19% from my buy price.

I have sold it at a loss of -₹4,037.6 after holding it for 394 days, I should not have bought it in the first place since it did not satisfy any of my rules. The earnings have dropped 82% from ₹57.03 to ₹10.24 and it is good that I have not added to stock when EPS dropped.

It is an integrated global pharmaceutical company with three business segments: Pharmaceuticals, Contract Research & Development services, and proprietary novel drugs.

Quick Heal Technologies

Buy Date: 17-Dec-2021

Qty: 43 Price: ₹227.8 EPS: ₹14.69 PE:15.5

I will not add to this stock even when the price drops.

I have purchased this stock since it has zero debt and cash of around ₹332cr after the buyback.

Buyback Date: 25-Oct-2022 Holding days: 312

Qty:12 Price: ₹300 EPS: ₹11.12 PE: 26.97

Quick Heal Technologies is an India-based IT security solutions company. It is engaged in offering software security products and solutions. The company serves clients in various industries including manufacturing. BFSI, healthcare, hospitality, educational institutions, government organizations, emerging e-commerce, and the service sector. The group reports the operating segments based on the target customer groups to bring Retail; Enterprise and Government; and Mobile. It has a business presence in India and foreign countries, of which maximum revenue is derived within India. Its product range consists of Quick Heal Total Security, Quick Heal AntiVirus Pro, Quick Heal Total Security for Mac, Quick Heal PCTuner 3.0, and Guardian NetSecure.

Cyient update

Ex-Dividend date 25-10-2022 ₹10 per share. Received ₹130 the cost basis is ₹9630.4.

I just wanted to try dividend investing, will check yearly to see how it performed.

Buy Date: 17-Oct-202296

Qty: 13 Price: ₹750.8 EPS: ₹43.83 Amount: ₹9760.4

Dividend Evaluation Checklist:
3.19	Dividend Yield: Ideally Between 3.5% and 6.5%
The dividend growth is not consistent year on year	Number of Consecutive Years of Dividend Growth: Ideally At Least 10
41.17%	Average Annual Dividend Growth: Ideally between 5% and 10%
12.62%	Average Annual Earnings Growth: Ideally in line with or above dividend growth rates.
54.78	Dividend Payout Ratio: Ideally less than 75%, except for REITs and MLPs
0.52	Debt to Equity Ratio: Ideally 1:1 or less
11.52	Net Margins: Ideally at least 5%
16.29	Return on Equity: Ideally at least 10%
949	Fair Value Estimate: Ideally trading below Morningstar’s Fair Value Estimate
750.8	Current Price

I will continue to invest only when EPS increases and the price falls.

I am going to sell it at Morningstar's Fair Value.

Cyient provides a variety of information technology, IT, and engineering services. The firm organizes itself into two segments based on customer type and reported as either service or design-led manufacturing revenue. Services are by far the largest activity. The industries served are aerospace and defense, communications, energy and utilities, transportation, medical and healthcare, semiconductor, and portfolio which focuses on the development and implementation of new technologies in all sectors. The majority of the company's revenue comes from America.